Purpose: To report the feasibility of performing hybrid intra-cavitary and interstitial (IC/IS) brachytherapy in patients with carcinoma cervix under trans-rectal ultrasound (TRUS) guidance.
Material And Methods: All patients who received an external beam radiotherapy (EBRT) dose of 50 Gy in 25 fractions with weekly chemotherapy, followed by a brachytherapy boost (21 Gy in 3 fractions) were prospectively included for analysis. IC/IS brachytherapy was performed using Fletcher style tandem and ovoid applicator with interstitial component under TRUS guidance. Parameters of implant quality analyzed included ability to insert tandem, ratio of needles loaded to the number of needles inserted, and incidence of uterine or organ at risk (OARs) perforation. Dosimetric parameters evaluated were dose to point A*, TRAK, D high-risk clinical target volume (HR-CTV), and D to OARs (bladder, rectum, and sigmoid). Width and thickness of the target was compared between TRUS (TRUS and TRUS) and MRI (MRI and MRI).
Results: Twenty carcinoma cervix patients treated with IC/IS brachytherapy were included for analysis. The mean HR-CTV volume was 36 cc. The median number of needles used were 6 (range, 2-10 needles). None of the patients had uterine perforation. Two patients had bowel and bladder perforation. The mean D HR-CTV and D HR-CTV were 87.3 Gy and 82 Gy EQD, respectively. The mean D to the bladder, rectum, and sigmoid were 80 Gy, 70 Gy, and 64 Gy EQD, respectively. The mean dose to point A* was 70.4 Gy EQD. The mean TRAK was 0.40. The mean TRUS (±SD) and MRI (±SD) were 4.58 cm (±0.44) and 4.49 cm (±0.50), respectively. The mean TRUS (±SD) and MRI (±SD) were 2.7 cm (±0.59) and 2.62 cm (±0.59), respectively. On statistical analysis, there was a significant correlation between TRUS and MRI ( = 0.93), and TRUS and MRI ( = 0.98).
Conclusions: TRUS-guided IC/IS brachytherapy is feasible and provides adequate coverage of the target, with acceptable doses to OARs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324591 | PMC |
| http://dx.doi.org/10.5114/jcb.2023.127816 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The influence of time and implants in high-dose rate image-guided adaptive brachytherapy for locally advanced cervical cancer.
Brachytherapy
January 2025
Department of Radiation Oncology, Institut Paoli-Calmettes, Marseille, France.
Purpose: To compare the clinical outcomes of two different schedules of modern image-guided adaptive brachytherapy (IGABT) in patients underwent chemoradiotherapy (CCRT) and high-dose rate (HDR) brachytherapy (BT) for locally advanced cervical cancer treated (LACC) METHODS AND MATERIALS: Data from medical records of all consecutive patients with histologically proven cervical cancer (FIGO 2018 stage IB-IVA) treated by HDR-BT after CCRT at our institution between 2016 and 2021 were reviewed.
Results: Two hundred and 8 patients with LACC FIGO 2018 stages (IB 20.7%; II 26.
Application value of personalized 3D printing vaginal model for the Image-guided adaptive brachytherapy of cervical cancer.
J Gynecol Oncol
November 2024
The 3th Ward of Radiotherapy Department, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China.
Objective: To explore the application value of using 3-dimensional (3D) printing (3DP) technology to create individualized vaginal molds for brachytherapy (BT) in high-dose-rate 3D cervical cancer through reverse engineering of needle placement.
Methods: Prospectively, 11 patients with cervical cancer were treated with 3DP-intracavitary/interstitial (IC/IS) BT using 3DP to create individualized vaginal molds. All patients were performed BT after completion of external beam radiotherapy (EBRT).
Factors Affecting D90 High-risk Clinical Target Volumes (HR-CTV dose) of Intracavitary and Interstitial Brachytherapy in Locally Advanced Cervical Cancer.
Clin Oncol (R Coll Radiol)
January 2025
Division of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Aims: Intracavitary brachytherapy alone covers a limited target volume; however, intracavitary and interstitial brachytherapy (IC/IS) can increase the dose coverage. We aim to assess the factors that impact D90 high-risk clinical target volume (HR-CTV) dose. We also assess clinical outcomes and toxicities for 3D image-based brachytherapy.
View Article and Find Full Text PDFAutomated planning of curved needle channels in 3D printed patient-tailored applicators for cervical cancer brachytherapy.
Phys Med Biol
November 2024
Department of BioMechanical Engineering, Delft University of Technology, Delft, The Netherlands.
Patient-tailored intracavitary/interstitial (IC/IS) brachytherapy (BT) applicators may increase dose conformity in cervical cancer patients. Current configuration planning methods in these custom applicators rely on manual specification or a small set of (straight) needles. This work introduces and validates a two-stage approach for establishing channel configurations in the 3D printed patient-tailored ARCHITECT applicator.
View Article and Find Full Text PDFDose Contribution to the Regional Lymph-Node Metastases and Point B from Intracavity and Interstitial Hybrid Brachytherapy in Locally Advanced Cervical Cancer.
Cancers (Basel)
June 2024
Department of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Purpose: Analyzing dose distributions to regional lymph-node metastases (RLNMs) in locally advanced cervical cancer (LACC) patients undergoing intracavitary and interstitial hybrid brachytherapy (IC/IS).
Methods: Dose distributions of eleven LACC patients with 38 RLNMs, and who received 38 IC/IS sessions were analyzed in EQD, considering RLNM positions and ipsilateral interstitial needles; these RLNMs, excepting the para-aortic region, were classified into four groups.
Results: RLNMs had a median of two ipsilateral interstitial needles per session.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!